Siegfried Holding AG - Company Profile
Powered by 
All the data and insights you need on Siegfried Holding AG in one report.
$295
- Save hours of research time and resources with
our up-to-date Siegfried Holding AG Strategy Report
- Understand Siegfried Holding AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Siegfried Holding AG (Siegfried) is a life science company. It is active in the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients (APIs). It manufactures APIs for the research-based pharmaceutical industry and corresponding intermediates and controlled substances. The company offers a comprehensive range of services to its partners including registration and manufacturing to packaging and logistics. It also offers development and production services for finished dosage forms including sterile filling. Siegfried has production facilities in the US, Switzerland, Malta, China, Germany, Spain and France. The company also offers its products in the US, Europe, and other countries. Siegfried is headquartered in Zofingen, Aargau, Switzerland.
Headquarters
Switzerland
Address
Untere Bruehlstrasse 4, Zofingen, 4800
Website
www.siegfried.ch
Telephone
41 62 7461111
No of Employees
3,933
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SFZN (SWF)
Revenue (2023)
$1.4B
3.4%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-27.9%
(2023 vs 2022)
Market Cap*
$4.4B
Net Profit Margin (2023)
XYZ
-30.3%
(2023 vs 2022)
* As of and is in US$
Siegfried Holding AG premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Drug Substance: | Contract Manufacturing |
| API | Supply Chain Management |
| Intermediates | Exclusive Synthesis |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In May, the company acquired a 95% stake in Dinamiqs. |
| 2023 | Corporate Changes/Expansions | In March, the company opened its new Development Center for Drug Products at its two Spanish sites in Barbera del Valles and El Masnou near Barcelona. |
| 2022 | Corporate Changes/Expansions | In September, the company announced the start of construction of a new large-scale production facility in Minden, Germany. |
Competitor Comparison
| Key Parameters | Siegfried Holding AG | Lonza Group Ltd | Perrigo Co Plc | Bachem Holding AG | Corden Pharma Switzerland LLC |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Ireland | Switzerland | Switzerland |
| City | Zofingen | Basel | Dublin | Bubendorf | Liestal |
| State/Province | - | - | - | - | Basel-Landschaft |
| No. of Employees | 3,933 | 17,896 | 9,140 | 2,006 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andreas Casutt, Ph.D. | Chairman | Executive Board | 2014 | 60 |
| Wolfgang Wienand Ph.D. | Chief Executive Officer | Senior Management | 2019 | 50 |
| Reto Suter, Ph.D. | Chief Financial Officer | Senior Management | 2017 | 52 |
| Jurgen Roos, Ph.D. | Chief Scientific Officer | Senior Management | 2019 | 55 |
| Marcel Imwinkelried | Chief Operating Officer - Drug Products | Senior Management | 2021 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward